©The Author(s) 2025.
World J Diabetes. Oct 15, 2025; 16(10): 109815
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.109815
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.109815
Figure 5 miR-375-3p inhibition abrogates the influence of glucotoxic pancreatic cell-derived exosomes on hepatocytes.
Hep1-6 cells were transfected with miR-375-3p mimics or control mimics for 48 hours using RNAi Max. A-C: Western blot analysis of AKT/GSK signaling and quantification of phosphorylated proteins; D: Glycogen content analysis in Hep1-6 cells. Hep1-6 cells were transfected with a miR-375-3p inhibitor or control inhibitor for 48 hours and treated with exosomes from low- or high-glucose-stimulated MIN-6 cells for 24 hours; E and F: Western blot analysis of AKT/GSK signaling and Rbpj protein levels; G: Densitometric quantification of the relative protein levels normalized to β-actin performed using ImageJ; H: Glycogen content analysis in Hep1-6 cells. The experiments were repeated three times. aP < 0.05, cP < 0.001. Western blot raw data in Supplementary material.
- Citation: Xu FZ, Dou L, Wu X, Xia CX, Yu DN, Man Y, Shen T, Huang XQ. Exosomal transfer of miR-375-3p from pancreatic β cells to hepatocytes impairs hepatic glycogenesis via Rbpj repression. World J Diabetes 2025; 16(10): 109815
- URL: https://www.wjgnet.com/1948-9358/full/v16/i10/109815.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i10.109815